⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVO News
Novo-Nordisk A/S
FDA approves Novo Nordisk's Awiqli®, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
prnewswire.com
NVO
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
globenewswire.com
NVO
Resolutions from the Annual General Meeting of Novo Nordisk A/S
globenewswire.com
NVO
Kalohexis Announces Publication in Frontiers in Endocrinology Defining Design Criteria for Next-Generation Melanocortin Drugs for General Obesity
prnewswire.com
NVO
Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
globenewswire.com
NVO
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
accessnewswire.com
LEXX
LLY
NVO
PFE
Accelerating GLP-1 Peptides to Market Through Integrated Formulation & Analytical Development, Upcoming Webinar Hosted by Xtalks
prnewswire.com
NVO
LLY
Form Health Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
businesswire.com
LLY
NVO
NOVUS Continues Leadership Expansion with Krithika Rosenthal as Managing Director, Strategy & Integrated Outcomes
prnewswire.com
NVO
DG
KHC
CHD
UPS
EBAY
Novo Nordisk A/S - share repurchase programme
globenewswire.com
NVO